Hantz Financial Services Inc. Sells 97,490 Shares of DexCom, Inc. $DXCM

Hantz Financial Services Inc. reduced its stake in DexCom, Inc. (NASDAQ:DXCM) by 96.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,289 shares of the medical device company’s stock after selling 97,490 shares during the period. Hantz Financial Services Inc.’s holdings in DexCom were worth $221,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the stock. Brighton Jones LLC lifted its position in shares of DexCom by 257.7% during the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after acquiring an additional 11,946 shares during the period. Integrated Wealth Concepts LLC raised its stake in DexCom by 6.3% in the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after purchasing an additional 196 shares in the last quarter. Empowered Funds LLC lifted its position in DexCom by 5.4% during the first quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock worth $577,000 after purchasing an additional 436 shares during the period. Focus Partners Wealth grew its stake in DexCom by 13.2% during the first quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock worth $493,000 after buying an additional 841 shares in the last quarter. Finally, Prime Capital Investment Advisors LLC bought a new position in DexCom in the 2nd quarter valued at about $229,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Leerink Partners reaffirmed an “outperform” rating and set a $92.00 price target on shares of DexCom in a report on Tuesday, December 16th. Wall Street Zen cut DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 16th. Wells Fargo & Company set a $93.00 price target on DexCom and gave the company an “overweight” rating in a research note on Friday, October 31st. Argus lowered their price target on DexCom from $100.00 to $90.00 and set a “buy” rating for the company in a report on Friday, November 7th. Finally, Canaccord Genuity Group set a $99.00 price objective on DexCom and gave the company a “buy” rating in a research note on Friday, October 31st. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and a consensus price target of $85.00.

Insider Transactions at DexCom

In other news, Director Richard Alexander Collins sold 2,906 shares of the business’s stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $59.05, for a total transaction of $171,599.30. Following the sale, the director directly owned 35,088 shares in the company, valued at approximately $2,071,946.40. The trade was a 7.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Bridgette P. Heller sold 1,012 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total transaction of $58,766.84. Following the completion of the transaction, the director owned 27,031 shares of the company’s stock, valued at approximately $1,569,690.17. This trade represents a 3.61% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 0.32% of the company’s stock.

DexCom Stock Up 0.1%

Shares of DXCM opened at $69.97 on Monday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.38 and a current ratio of 1.56. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $93.25. The stock has a market capitalization of $27.29 billion, a price-to-earnings ratio of 38.87, a PEG ratio of 1.25 and a beta of 1.49. The stock has a fifty day moving average of $68.67 and a 200-day moving average of $70.18.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.